RESUMEN
BACKGROUND: Skin barrier dysfunction may precede infantile development of clinical atopic dermatitis (AD). Early-life emollient therapy to enhance barrier function may prevent or modify AD development in high-risk infants. OBJECTIVES: (a) To determine whether daily full-body application of an emollient with ceramide and amino acids (study emollient) can reduce the cumulative AD incidence compared to standard skin care at 1 year of age. (b) To evaluate the study emollient's effect on skin barrier function, natural moisturizing factor and the microbiome using non-invasive biophysical and biochemical techniques. METHODS: We performed a single-centre, investigator-blinded, randomized controlled trial enrolling infants at high risk for AD development determined by family history. The intervention was full-body once-daily application of the study emollient. The control arm was asked to not apply full-body emollient regularly and only use an emollient of their choice for dry skin. The primary outcome was the cumulative incidence of AD diagnosed at 12 months by a blinded investigator. RESULTS: Less than half the target sample size was enrolled (n = 100, goal sample was 208) with 28% lost to follow-up. Across all clinical end points, a numerical trend was observed in favour of the intervention, although not statistically significant likely due to lack of power from under-enrolment. AD was diagnosed in 13.2% vs. 25.0% at 12 months (P = 0.204) and 19.4% vs. 31.0% at 2 years (P = 0.296) in intervention vs. control groups, respectively. There were no significant differences between groups in skin barrier or microbiome assessments. While there were no serious adverse events, there were more cases of reported contact dermatitis in the intervention vs. control arms, 9.3% vs. 4.3%, respectively; however, these events were not related to the study emollient and most mild in severity. CONCLUSION: The observed trends suggest a protective effect of daily study emollient therapy compared to control.
Asunto(s)
Dermatitis Atópica/prevención & control , Emolientes/uso terapéutico , Aminoácidos , Ceramidas , Dermatitis Atópica/epidemiología , Emolientes/farmacología , Femenino , Proteínas Filagrina , Humanos , Lactante , Recién Nacido , Proteínas de Filamentos Intermediarios , Masculino , Prevención Primaria , Medición de Riesgo , Método Simple Ciego , Fenómenos Fisiológicos de la Piel/efectos de los fármacosRESUMEN
BACKGROUND: The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument measuring the severity of clinical signs in atopic dermatitis (AD). The EASI was identified as one of the best-validated outcome measures for AD; however, no previous studies address how to interpret the EASI score for clinical use. OBJECTIVES: To evaluate the interpretability and the ease of use of the EASI. METHODS: A retrospective analysis of paediatric and adult patients with AD was performed. Interpretability was evaluated by stratifying the EASI scores according to the Investigator's Global Assessment. The severity strata displaying the highest kappa coefficient of agreement were then selected as the recommended EASI band. The time to administer the EASI was recorded in a subgroup of patients. RESULTS: The suggested severity strata for the EASI are as follows: 0 = clear; 0·1-1·0 = almost clear; 1·1-7·0 = mild; 7·1-21·0 = moderate; 21·1-50·0 = severe; 50·1-72·0 = very severe (κ = 0·75). The EASI was also found to be acceptable in terms of ease of use, with assessments by trained investigators taking approximately 6 min. CONCLUSIONS: Our study provides the first guide for interpreting the EASI score. It enables translation of the EASI numerical output into an AD global severity state that should be more meaningful to providers and patients. Along with a short administration time, the EASI demonstrates adequate feasibility, further supporting its use in clinical trials.
Asunto(s)
Dermatitis Atópica/diagnóstico , Índice de Severidad de la Enfermedad , Adolescente , Adulto , Anciano , Niño , Estudios de Factibilidad , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Estudios Retrospectivos , Sensibilidad y Especificidad , Adulto JovenRESUMEN
Methylecgonine is a common metabolite of cocaine in man. We prepared methylecgonine and developed thin-layer chromatographic and gas-chromatographic methods for its detection in urine. Seventy urine specimens from our drug screening laboratory were tested by our method and by EMIT. Both methods were positive for 26 urines, and both were negative for 42 urines. The other two urines were shown to contain cocaine by GC/MS, and no detectable metabolites. We thus demonstrated that detection of methylecgonine and cocaine is as sensitive a test for cocaine use as EMIT.